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G protein-coupled receptors (GPCRs) constitute targets for ~34% of approved drugs. The 
muscarinic acetylcholine M2 receptor (M2R) activates G protein-coupled receptor inward 
rectifying potassium (GIRK) channels in the central nervous system and heart. Membrane 
potential modulates agonist potency at several GPCRs. However, the mechanism underlying 
the voltage sensitivity remains debated. A highly conserved aspartate residue (D2.5069) has 
been proposed to mediate the voltage-sensitivity of the M2R, although the low expression of 
D69 mutants has complicated further functional investigations.  
Dopamine D2 and D3 receptors (D2R and D3R) are pre- and postsynaptic inhibitory receptors 
in the central nervous system, involved in locomotion, cognition and endocrine functions. 
D2R antagonists and weak partial agonists are used clinically as antipsychotics but are 
associated with several side effects. Various strategies have been suggested to reduce the 
side-effect profile of novel antipsychotic drugs. One such strategy includes the selective 
targeting of non-canonical signaling pathways, e.g., the β-arrestin pathway, while leaving the 
classical, G protein pathway, undisturbed. Additionally, binding affinity and kinetics at the 
D2R, as well as ligand lipophilicity, have been suggested to be of significance in determining 
the side-effect liability of antipsychotics.  
In the thesis, M2R, D2R and D3R were investigated using two-electrode voltage-clamp in 
Xenopus laevis oocytes co-expressing the respective receptor and GIRK channels. M2R 
carrying a charge-neutralizing D69N mutation demonstrated a voltage-dependent shift of 
agonist-potency, similar to the wild type M2R. This finding is in line with a recent alternative 
hypothesis, which implicates three tyrosine residues in the M2R voltage sensor. The proposed 
β-arrestin-selective partial D2R agonist, UNC9994, was found to be a weak partial- and 
almost full agonist at D2R and D3R mediated GIRK activation, respectively. These findings 
are incongruent with β-arrestin-selectivity and suggest that the promising effects of 
UNC9994 in animal models of psychosis may be related, at least in part, to involvement of 
the D3R. Finally, the partial D2R agonist positron emission tomography ligand, SV-III-130, 
demonstrated an insurmountable, yet competitive, binding mechanism at the D2R. Mutations 
of residues in a secondary binding pocket, engaging the secondary pharmacophore, abolished 
the insurmountable binding. Kinetic models incorporating an irreversible, SV-III-130-bound 
state captured the experimentally observed data. Molecular dynamics simulations suggested 
that D2R extracellular linkers participate in an induced-fit binding mechanism.  
In summary, the thesis addresses the mechanism of voltage-dependent agonist-potency at 
GPCRs and contradicts earlier reports of a β-arrestin-selective action of the experimental 
antipsychotic, UNC9994, at the D2R. Finally, a two-step induced-fit binding mechanism was 
demonstrated for the aripiprazole analogue, SV-III-130, at the D2R. The findings may guide 
further mechanistic investigations and provide insights for the development of novel 
diagnostic and therapeutic GPCR ligands.   
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LIST OF ABBREVIATIONS 
5-HT1-7R Serotonin 1-7 receptors 
AT1R Angiotensin II type 1 receptor 
cAMP Cyclic adenosine monophosphate  
D1-5R Dopamine D1-5 receptors 
EC50 Half maximal effective concentration 
ECL1-3 Extracellular loops 1-3 
Emax Intrinsic activity 
EPS Extrapyramidal symptoms 
ERK1 Extracellular signal-related kinase 1 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
GABAB1-2R Metabotropic γ-aminobutyric acid receptor, subunits 1-2 
GAP Guanosine triphosphatase accelerating proteins 
GPCR G protein-coupled receptor 
GIRK G protein-coupled inward rectifier potassium channel 
GDP Guanosine diphosphate 
GTP Guanosine triphosphate 
GRK2 G protein-coupled receptor kinase 2 
GSK3β Glycogen synthase kinase 3β 
IC50 Half maximal inhibitory concentration 
IP3 Inositol 1,4,5-trisphosphate 
Kd Dissociation constant 
Ki Inhibition constant 
kobs Observed association rate 
koff Dissociation rate constant 
kon Association rate constant 
M1-5R Muscarinic acetylcholine M1-5 receptors 
mGlu1-3R Metabotropic glutamate receptors 1-3 
MS-222 Tricaine methanesulfonate 
NMDA N-methyl-D-aspartate 
µ-OR µ-Opioid receptor 
 
 
OBP Orthosteric binding pocket 
PCP Phencyclidine 
PET Positron emission tomography 
PIP2 Phosphatidylinositol 4,5-bisphosphate 
PKB Protein kinase B 
PTX Pertussis toxin 
PTX-S1 Catalytic subunit of pertussis toxin 
PPHT 2-(N-phenethyl-N-propyl)amino-5-hydroxytetralin 
RGS Regulator of G protein signaling 
SBP Secondary binding pocket 
TEVC Two-electrode voltage-clamp 





1.1 G-PROTEIN COUPLED RECEPTORS 
During the 20th century, theories of receptor-ligand interactions were derived from 
experiments on myocytes and glands. In 1972, the β-adrenergic G-protein coupled receptor 
(GPCR) was identified and purified by Lefkowitz et al. (1). This was followed by structural 
determination of the photon-sensitive visual rhodopsin, and later cloning of the β2 adrenergic 
receptor (2). GPCRs, consisting of seven transmembrane helices, enable transmission and 
amplification of extracellular factors to intracellular signals by canonical, i.e., G-protein, and 
non-canonical, e.g., β-arrestin, pathways. The widespread expression of GPCRs in a 
multitude of cells and their involvement in disease support pharmacological targeting; 
currently 34% of all approved drugs target GPCRs (3).  
1.2 DIMENSIONS OF RECEPTOR PHARMACOLOGY 
Physiological, or pathological, receptor expression in vivo determines the target area of a 
receptor ligand. GPCRs involved in the modulation of neuronal signaling typically span the 
cell membrane and are located either pre- and/or postsynaptically. The ligand may either 
target one specific type of receptor (receptor-specific), mainly prefer one type of receptor 
(receptor-preferring) or target a whole span of different receptors (multireceptor, or “dirty”, 
targeting) (Fig. 1A). Most clinically used GPCR ligands interact with several receptors. For 
example, most antipsychotic drugs bind to dopamine, but also to serotonin, α-adrenergic, 
muscarinic acetylcholine and histaminergic receptors, each interaction associating with 
different clinical (side-)effects (see e.g. (4)).  
Receptors may exist as monomers, homomers or heteromers, and only signal as obligate 
heteromers (Fig. 1B). This was first demonstrated for the G protein-coupled γ-aminobutyric 
acid receptor (GABABR), which requires co-expression of GABAB1R subunits with 
GABAB2R subunits to form functional receptors (5). Based on the assumption that 
heteromers are selectively expressed in regions of interest, ligands targeting specific 
heteromers may reduce the degree of side-effects (6).  
When the ligand is in the vicinity of a targeted receptor, the probability of a binding event 
occurring is dependent on the ligand concentration (L), the receptor concentration (R), the 
ligand association rate constant (kon) and the ligand dissociation rate constant (koff),  





where RL is the ligand-bound receptor (Fig. 1C). Assuming a one-step binding mechanism, 
the binding rate constants dictate the dissociation constant (Kd; koff/kon). Both association and 
dissociation rate constants are critically dependent on the amino acid residues in the access 
pathway to the receptor binding site. An example illustrating the role of the first extracellular 
loop (ECL1) in regulating ligand entry and egress was illustrated by increased association and 
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dissociation rates of the antipsychotic drug risperidone at the dopamine D2 receptor (D2R) 
following mutation of W100 (7). 
Typically, the ligands bind to amino acid residues in one or several receptor cavities, either 
by a single- or a multistep-process, respectively. An example of the latter is heterobivalent 
ligand binding (8); illustrated by a ligand composed of two (primary and secondary) 
pharmacophores, i.e. ligand fragments with affinities to macromolecules, which bind with 
different affinities to two distinct receptor sites (the primary or orthosteric binding pocket; 
OBP and the secondary binding pocket; SBP) respectively (Fig. 1D). The endogenous ligand 
typically binds to the OBP, activating the receptor. Depending on the affinities of the two 
pharmacophores to the OBP and SBP respectively, two different heterobivalent binding 
modes are possible; high affinity of the primary pharmacophore to the OBP would allow for 
an “abII” binding mode, whereas a high affinity of the secondary pharmacophore to the SBP 
would facilitate an “abI” binding mode (8)(illustrated in Fig. 1D).  
Induced-fit binding is another multistep mechanism, where the ligand primary 
pharmacophore first binds to the OBP causing a conformational rearrangement of the 
receptor, which allows for subsequent binding of the secondary pharmacophore to the SBP 
(9)(illustrated in Fig. 1E). Such induced-fit binding may entail a prolonged drug residence 
time in vivo (10).  
The receptor-bound ligand may elicit a spectrum of responses depending on its intrinsic 
activity (Emax; Fig. 1F). An agonist could demonstrate supramaximal, full or partial efficacy; 
different amplitudes of responses, as compared to the response evoked by a reference full 
agonist (typically the endogenous ligand). A neutral antagonist has no efficacy and rather 
competes with agonists to abolish the response. Several antipsychotic drugs demonstrate 
partial agonist or antagonist features at the D2R, while antagonizing serotonin 2 receptors (5-
HT2Rs) (11). In addition, inverse agonists reduce the constitutive receptor activity; i.e., 
inhibit the background signaling of the receptor in the absence of an agonist. β-blockers 
demonstrating inverse agonism, e.g. propranolol, act at β-adrenergic receptors in the heart 
and skeletal muscles, and are used to reduce tachycardia and essential tremor (12, 13).  
Allosteric GPCR ligands may interact with separate, allosteric binding sites to modulate both 
the affinity and efficacy of ligands at the OBP (14, 15). For the GABABR, CGP7930 was one 
of the first reported positive allosteric modulators (16). Allosteric GPCRs modulators may 
affect endogenous ligand-receptor interactions only subtly, thereby allowing for additional 
strategies of targeting a range of conditions, including e.g. inflammation, psychosis, addiction 
and nociception (see (17)).  
At the signaling level, a ligand could activate any of the various G protein subtypes, e.g. Gαs, 
Gαi, Gαo, Gαq, Gz, Golf, Gα12/13, or the non-canonical β-arrestin pathway, with differential 
efficacies (Fig. 1G). Agonist-dependent G protein signaling bias has been demonstrated in 
vitro (18). Biased-signaling ligands, i.e. ligands preferentially activating either G protein or β-
arrestin pathways, may be of importance in reducing side-effects and potentiating therapeutic 
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drug effects. Oliceridine is a G protein-biased µ-opioid receptor (µ-OR) agonist that has been 
suggested to reduce constipation and respiratory depression, while maintaining the 
antinociceptive effect (19).  
 
Figure 1. Summary of key dimensions of receptor-ligand interaction. A) Receptor selectivity. Left, the selective 
ligand (green) only binds to one receptor (blue). Right, the non-selective ligand (red) binds to all receptors. B) 
Heteromer-dependent signaling. Left, ligand binding to the monomer does not evoke a response. Right, ligand 
binding to the heteromer evokes a response. C) Association and dissociation rate constants dictate the 
dissociation constant Kd. Note that the Kd ratio could be identical for the low koff/low kon and the high koff/high kon 
examples. D) Heterobivalent ligand binding, with primary (a) and secondary (b) pharmacophores of a bitopic 
ligand (a-b) interacting with two distinct receptor binding sites; the OBP and the SBP respectively. 
Mechanistically, either the secondary (black arrow) or the primary pharmacophore (red arrow) may bind the 
receptor first, described as abI- and abII-mechanisms respectively (8). E) Induced-fit binding is viewed as an 
initial binding event between the primary pharmacophore (a) and the OBP (red arrow), followed by a 
conformational change allowing binding of the secondary pharmacophore (b) to the SBP (9)(black arrow). Note 
that the latter event reverses only slowly (low koff). F) Agonist efficacy (or intrinsic activity). Following receptor-
ligand interaction, the downstream signaling is fully induced by an agonist (green), partially induced by a 
partial agonist (yellow), abolished by an antagonist (blue) and reduced below the baseline (constitutive) level by 
an inverse agonist (red). G) Biased signaling. The ligand activates both G protein (green) and β-arrestin 
signaling pathways (black). Details are not drawn to scale.  
1.3 G PROTEIN-SIGNALING PATHWAYS 
1.3.1 Activation of G protein signaling pathways  
GPCRs are recognized by their ability to induce G protein mediated signaling following 
activation. Ligand-activated GPCRs gain guanine-nucleotide exchange factor (GEF) 
properties, releasing guanosine diphosphate (GDP) from heterotrimeric G protein complexes 
of GαGDP/Gβγ (see (20)). This promotes binding of guanosine triphosphate (GTP) to Gα, 
inducing an activating conformational change, and possibly separating the Gα and Gβγ 
proteins (21). Depending on the G protein subtype, i.e. Gαs or Gαi/Gαo, GαGTP stimulates or 
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inhibits adenylate cyclase (AC) which converts ATP into 3’,5’-cyclic AMP (cAMP). The Gα 
protein stimulating AC, Gαs, may be ADP-ribosylated and activated by the V. Cholera toxin 
(22, 23), whereas the AC inhibitory Gαi/Gαo proteins may be ADP-ribosylated and 
inactivated by the B. pertussis toxin (PTX)(24, 25). Historically, this has facilitated the 
isolation and study of selected Gα proteins. Downstream of the GPCR, cAMP binds to, and 
activates protein kinase A, in turn phosphorylating the cAMP-response element binding 
protein, which binds to genomic cAMP response elements and induces transcription. Also, 
cAMP may directly activate cyclic-nucleotide gated channels (26). In similar, Gβγ proteins 
modulate ion channel activities, e.g. of L- and T-type voltage-gated calcium channels, and 
activate G protein-coupled inward rectifying potassium 1-4 (GIRK1-4) channels (27, 28).  
1.3.2 G protein-coupled inward rectifying potassium channels  
GIRK1-4 are expressed in the central nervous system and contribute to neuronal 
hyperpolarization (29, 30). Functional channels consist of GIRK1-4 subunit heterotetramers 
(with exception of GIRK2; able to form homotetramers), each consisting of two 
transmembrane helices (30, 31). For GIRK channel activation, phosphatidylinositol 4,5-
bisphosphate (PIP2) is required in addition to Gβγ (32). Also, GIRK channels are modulated 
by sodium ions, which might serve as a mechanism to hyperpolarize the cell following 
depolarization-induced sodium influx (33, 34). The specificity between G protein and GIRK 
channel activation is believed to be due to the higher rate of G protein activation, and thereby 
Gβγ generation, by Gαi/Gαo-coupled receptors as compared to Gq- and Gs-coupled receptors 
(35).  
1.3.3 Termination of the G protein signaling cascade  
Signal termination is evoked by the GTPase activity intrinsic to Gα proteins, hydrolyzing 
GTP into GDP and subsequently releasing inorganic phosphate. This is followed by 
sequestration of Gβγ proteins, which reform with Gα proteins. By stabilization, GTPase 
accelerating proteins (GAPs), including the regulator of G protein signaling (RGS) family, 
augment the catalytic activity of the Gα GTPase domain and thereby decrease the life time of 
the active, GTP-bound complex (see (20)). Structurally, the RGS domain consists of nine α-
helices, although there are functional differences between the GAPs; e.g. RGS4, being pre-
coupled to GIRK1/2 channels, potently accelerates G protein dependent gating, whereas the 
free cytosolic RGS3 only accelerates G protein dependent gating with 100-fold lower potency 
(36). Beyond modulation of AC by Gαs and Gαi/Gαo pathways, the Gαq protein activates 
phospholipase Cβ, hydrolyzing PIP2 to diacylglycerol and inositol 1,4,5-trisphosphate (IP3). 
Following activation of the IP3 receptor, located in the membrane of the endoplasmatic 
reticulum, Ca2+ is released to the cytosol, inducing transcriptional effects through 
Ca2+/calmodulin-dependent protein kinase II. Furthermore, a diverse array of G proteins have 
been characterized with a multitude of functions; e.g. activation of Gα12/13 proteins have been 
related to cell structure functions, e.g. actin remodeling (37). Finally, the differential 




1.4 NON-CANONICAL GPCR SIGNALING BY ΒETA-ARRESTINS 
Active GPCRs recruit GPCR kinases, e.g. GPCR kinase 2 (GRK2), responsible for GPCR 
phosphorylation and signal termination. GPCR phosphorylation enhances the recruitment of 
β-arrestin 1 and 2 to the GPCR, which induces GPCR desensitization (see (38)). In addition, 
β-arrestins activate downstream signaling pathways, separate from those activated by G-
proteins, e.g. nuclear factor kappa-light-chain-enhancer of activated B cells and tumor 
suppressor protein p53, regulating cell metabolism, mitochondrial function and synaptic 
plasticity in neurons (39-41). In addition, both G protein and β-arrestin signaling activate the 
extracellular signal-related kinase 1 (ERK1) pathway albeit with different kinetics; the former 
induces a rapid activation and deactivation, whereas the latter induces a slow activation and 
prolonged response (42, 43). Also, the β-arrestin-activated ERK1 remains cytoplasmic, as 
compared to the G protein-induced ERK1, which translocates to the nucleus (42, 43). G 
protein-independence of β-arrestin downstream signaling has been proposed (44, 45), 
although an investigation using mammalian cell lines with genetically deleted Gαs/Gαq/Gα12 
in conjunction with the Gαi/o-inactivating PTX demonstrated G protein-dependence of β-
arrestin signaling through ERK1 (46).  
Antipsychotic effects of D2R antagonists have been related to β-arrestin signaling, whereas 
extrapyramidal symptoms (EPS; i.e. dystonia, akathisia, tremor and tardive dyskinesia) have 
been suggested to result from interference with G protein signaling (45, 47). The mood 
stabilizer lithium has been proposed to inhibit glycogen synthase kinase 3β (GSK3β) 
signaling via modulation of a signaling complex consisting of β-arrestin, protein phosphatase 
2A and protein kinase B (PKB) (44). At cardiomyocyte angiotensin II type 1 receptors 
(AT1R), activation of β-arrestin signaling conferred positive inotropic effects, although these 
were counteracted by G protein-signaling activation (48). Thus, further development of β-
arrestin-selective AT1R and D2R ligands for cardiac failure and schizophrenia may prove 
valuable. In contrast, at the µ-OR, G protein signaling was related to analgesic effects, 
whereas β-arrestin signaling was related to gastrointestinal and respiratory adverse effects 
(19).  
1.5 MUSCARINIC ACETYLCHOLINE RECEPTORS  
Acetylcholine is the endogenous agonist at metabotropic muscarinic acetylcholine M1-5 
receptors (M1-5R), which are structurally highly homologous, but differ in G protein 
signaling; M1R, M3R and M5R activate Gαq, whereas M2R and M4R activate Gαi, (49). M1-5R 
are expressed in the peripheral and central nervous system in varying degrees (see (50) for 
review). M1R is expressed in the cortex and the striatum, and is involved in regulating 
dopamine release from substantia nigra. M1R
-/- mice display basal and amphetamine-induced 
hyperlocomotion as compared to wild type (WT) mice (51)). M2R and M3R are involved in 
parasympathetic nervous system responses (52). For example, cardiac acetylcholine release, 
which induces M2R activation, Gβγ release and subsequent GIRK channel activation, 
contributes to membrane repolarization and a negative chronotropic effect (53). The 
inhibitory M4R is present in cholinergic interneurons in the striatum, reducing dopaminergic 
tone and inhibiting movement (54). For hypodopaminergic conditions, e.g. Parkinson’s 
disease, pharmacological inhibition of the M4R may prove valuable (55). The M5R is 
expressed in dopaminergic neurons in the substantia nigra and ventral tegmental area, and has 
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been suggested involved in opioid reward; M5R
-/- mice displayed reduced reward from 
morphine administration (56). Although high degrees of homology between the M1-5R have 
complicated the development of receptor subtype-specific ligands, recently reported crystal 
structures of M1R and M4R (57), M2R (58), M3R (59) and M5R (60) will likely facilitate in 
silico ligand development.  
1.6 VOLTAGE-SENSITIVITY OF GPCRS 
Voltage-gated and, to some extent, ligand-gated ion channels functionally depend on voltage-
sensitivity (61). Interestingly, in 2003, also GPCRs were demonstrated to be voltage-
sensitive; acetylcholine potency at the M2R was reduced at depolarized potentials in GIRK 
activation- and radioligand binding assays (62). In contrast, the M1R was found to possess an 
inverse voltage-dependence, binding acetylcholine with increased affinity at depolarized 
potentials (62). Experiments on metabotropic glutamate 1-3 receptors (mGlu1-3R) revealed 
differential voltage-dependent agonist potencies. Following depolarization, glutamate 
potency at the Gαq-coupled mGlu1R increased, whereas glutamate potency decreased at the 
Gαi-coupled mGlu3R (63). In search of a voltage-sensor, gating-charges were recorded in the 
M2R, and were consistent with the voltage-sensitivity of ligand binding (64). The voltage-
sensitivity of ligand potency was subsequently demonstrated in D2R, histamine H3 and H4 
receptors, generalizing the concept to include numerous GPCRs (65-67). Further 
investigations revealed ligand-specificity of the voltage-dependent shift in agonist potency at 
the D2R; in contrast to aporphines, which retained potency and efficacy at -80 mV and at 0 
mV, several other D2R agonists demonstrated reduced potencies and, for some agonists, also 
reduced Emax at depolarized potentials (68).  
In search for the GPCR voltage-sensor(s), a well-conserved aspartate residue, D2.5069 
(Ballesteros-Weinstein nomenclature; (69)), was proposed to confer the voltage-sensing 
properties of the M2R, as D69 is involved in coordinating a charged sodium ion within the 
seven transmembrane helices (70). M2R D69A demonstrated no gating currents, although 
surface expression of the mutant receptor was reduced (71). Additional investigations, based 
on molecular dynamics simulations, supported the role of the D69 residue in regulating M2R 
voltage-sensitivity (72). Recently, tyrosine-phenylalanine substitution of three residues 
(Y3.33104, Y6.51403 and Y7.39426) surrounding the OBP, were demonstrated to eliminate the 
voltage-dependent agonist potency (73). However, the involvement of the D2.5069 in the 
voltage-sensing of the M2R, and other GPCRs, still remains unclear.  
The voltage-dependent agonist potency at GPCRs explains a cardiac phenomenon; the 
depolarization-induced decrease of acetylcholine-dependent potassium current in sinoatrial 
node cardiomyocytes (74). Based on electrophysiological investigations of atrial 
cardiomyocytes, this finding is mechanistically related to the lower potency of acetylcholine 
at M2R in depolarized cells (75).  
1.7 DOPAMINE RECEPTORS 
In the 1950s, Arvid Carlsson discovered the ability of dopamine to reverse loss of motor 
functions following reserpine-induced depletion of synaptic vesicles (see (76) for an 
overview). This finding distinguished dopamine from the related monoamine serotonin and 
paved the way for understanding the role of dopamine in modulating cognition, mood, 
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learning, memory, motor and endocrine functions (77, 78). Dopamine receptors are classified 
by their main signaling pathways; D1-like receptors (D1R and D5R) activate stimulatory 
Gαs/olf and D2-like receptors (D2R, D3R and D4R) activate inhibitory Gαi/o proteins (79). The 
regional expression of dopamine receptors differs; postmortem autoradiography studies 
indicated high expression levels of D1R and D2R in the caudate nucleus and putamen, with 
D1R concentrated to the medial caudate nucleus in contrast to the more evenly distributed 
D2R (80). Additionally, D1R, more densely expressed in cortical regions as compared to D2R 
(80), has been related to physiological and pathological cognitive functioning (81-83). D1R is 
mainly postsynaptically expressed, in contrast to D2R, which is present both pre- and 
postsynaptically (77). Prominent heterodimerization of dopamine receptors, e.g. D1R-D3R, 
D1R-D2R, and D2R-D3R provides additional complexity to receptor subgroup signaling (84, 
85). The reported crystal structures of D2-like receptors; D2R (7), D3R (86) and D4R (87), 
allow for in silico design of selective ligands.    
Dopaminergic signaling is mediated by three separate pathways, the nigrostriatal, the 
mesocorticolimbic and the tuberoinfundibular pathway (see (88) for review). Briefly, the 
nigrostriatal pathway consists of dopamine neurons in substantia nigra pars compacta 
projecting to the caudate nucleus and putamen, modulating motor functions but also memory, 
and to some extent reward. The mesocortical and mesolimbic pathways consist of dopamine 
neurons in the ventral tegmental area projecting to the cortex, modulating executive 
functions, and to the nucleus accumbens, mediating reward and positive reinforcement. The 
tuberoinfundibular pathway consists of dopamine neurons of the hypothalamic arcuate 
nucleus projecting to the hypophysis.  
1.8 DOPAMINE RECEPTORS AS TARGETS 
1.8.1 Dopaminergic disorders  
Numerous pathological conditions, e.g. Parkinson’s disease, hyperprolactinemia, 
Huntington’s disease, schizophrenia, bipolar disorder and addiction are related to hypo- or 
hyperactive dopaminergic signaling (89-94). For schizophrenia, the dopamine hypothesis has 
been revised multiple times. Hyperactive mesolimbic dopamine signaling has been proposed 
to be responsible for positive symptoms (hallucinations, delusions and thought disorder) 
while hypoactive mesocortical dopamine signaling would explain negative (flattened affect, 
avolition, alogia) and cognitive symptoms (95). Accumulating evidence from neuroimaging, 
genome-wide association- and epidemiological studies has updated the dopamine hypothesis. 
Genetic variants and mutations are thought to drive a presynaptic increase in dopamine 
levels, which increase the probability of developing psychotic disorders, including 
schizophrenia, and to disturb the perception of external stimuli (96). An alternative 
hypothesis of schizophrenia, glutamatergic dysregulation, was based on N-methyl-D-
aspartate (NMDA)-antagonists, e.g. phencyclidine (PCP) and ketamine, replicating the 
positive, negative, and cognitive symptoms seen in schizophrenia (97). Finally, the 
kynurenine hypothesis involves glutamatergic dysregulation related to increased 
concentrations of kynurenic acid, an endogenous NMDA-antagonist, in patients with 




1.8.2 Clinically used antipsychotics 
The mainstay of pharmacological treatment of schizophrenia is currently D2R blockade, by 
antagonists, or weak partial agonists. First-generation or typical antipsychotic drugs, based on 
the first agent chlorpromazine discovered in 1952, are recognized as ligands with high D2R 
potency, prone to evoke EPS at high concentrations (99). In positron emission tomography 
(PET) studies of schizophrenic patients treated with typical antipsychotic drugs, the D2R 
occupancy was 70-89%, with higher receptor occupancy related to EPS (100). This 
seemingly narrow therapeutic interval stimulated investigations to explain- and decrease the 
EPS propensity of antipsychotic drugs. The second-generation or atypical antipsychotics, 
initially based on clozapine (first discovered in 1958), demonstrated reduced EPS 
propensities (101). The typical/atypical drug classification has been questioned, as this 
classification does not fully explain the EPS frequency (102). In addition, third-generation 
antipsychotics refer to drugs demonstrating partial D2R agonism, e.g. aripiprazole, and more 
recently also brexpiprazole, cariprazine and lumateperone (103). Due to more pronounced 
presynaptic D2R receptor reserves, a partial agonist may activate autoreceptors to a larger 
extent than postsynaptic receptors, thereby decreasing dopamine synthesis and release (103). 
Alternatively, assuming increased synaptic dopamine concentrations in the mesolimbic 
pathway, partial agonists may functionally antagonize D2Rs, based on their low Emax. 
Oppositely, the partial agonists may activate D2Rs in the mesocortical pathway, where low 
dopamine concentrations prevail (103-105). This concept of functional selectivity motivates 
further development of partial D2R agonists as therapeutic “dopamine stabilizers”. 
In 2000, experimental radioligand binding studies of antipsychotics at the D2R suggested that 
atypical antipsychotics dissociate up to 100 times more rapidly as compared to typical 
antipsychotics; this “fast-off” feature was proposed to facilitate dopamine rebinding at D2R 
following drug dissociation, thus preserving the physiological dynamics of dopamine 
signaling (106). In addition, this hypothesis opposed the theory of 5-HT2R antagonism 
reducing the EPS propensity, as D2R occupancy had the highest correlation with EPS 
propensity (107). The “fast-off” hypothesis was reinvestigated by analysis of binding kinetics 
of 17 antagonists at the D2R, using the Gβγ-mediated GIRK activation assay. Rapid 
chlorpromazine dissociation from the D2R and a mere twofold difference in dissociation 
kinetics between chlorpromazine and clozapine were demonstrated (108), in stark contrast to 
previous findings by Kapur and Seeman (106). Extended analyses of antipsychotic drug 
dissociation rates from the D2R and validation of the GIRK assay results continued to 
challenge the “fast-off” hypothesis (109), instead proposing the variation in dissociation 
kinetics and extents of reversibility possibly related to D2R antagonist lipophilicity (110). A 
following investigation, using a kinetic assay observing D2R antagonist competition with the 
fluorescent D2R agonist 2-(N-phenethyl-N-propyl)amino-5-hydroxytetralin hydrochloride 
(PPHT)-red, correlated antipsychotic drug association rates at the D2R with EPS odds ratios 
and dissociation rates with the risk of hyperprolactinemia. Pronounced drug-D2R rebinding 
due to high association rates, in the context of limited drug diffusion, was proposed to be 
mechanistically related to a high EPS propensity (111). These findings have been questioned, 
based on the slow association rate of the used agonist PPHT and the generalization of kon 
dictating EPS propensities (112). Different determinants of association rates have been 
suggested, including ligand lipophilicity, diffusion and ligand conformation (113-115).   
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1.8.3 β-arrestin-biased partial agonists as experimental antipsychotics 
The observation that a range of GPCRs were able to affect both canonical G protein, and non-
canonical β-arrestin, signaling pathways opened the field of biased signaling (88). Numerous 
antipsychotic drugs are able to antagonize β-arrestin signaling at the D2R, in addition to 
antagonizing G protein signaling (47). A reduction of the β-arrestin downstream effector 
PKB has been suggested in patients with schizophrenia and the mood stabilizer lithium has 
been proposed to modulate PKB-GSK3β-signaling (44, 116). At this point, development of β-
arrestin-biased ligands opened for further probing of non-canonical GPCR signaling 
pathways in vivo.  
In 2011, a series of β-arrestin-selective aripiprazole analogues; UNC9994, UNC9975 and 
UNC0006, was synthesized at the University of North Carolina, and demonstrated to be 
devoid of G-protein signaling activity at the D2R (45). Furthermore, UNC9994 elicited 
antipsychotic properties in a mouse model of PCP-induced locomotion; this feature was fully 
reversed in β-arrestin-2-/- mice, supporting the hypothesis that β-arrestin-2-dependent D2R 
signaling is involved in mediating antipsychotic drug effects (45). UNC9994 was reported to 
recruit β-arrestin-2 to D2R only in the presence of GRK2, especially relevant for cortical 
tissue with high expression levels of β-arrestin-2 and GRK2 as compared to the striatum, 
where UNC9994 is an antagonist at β-arrestin-2 D2R signaling. The resulting cortical β-
arrestin-2-selective D2R agonism increased fast-spiking interneuron activity and was 



















2 AIMS OF THE THESIS 
The thesis investigates GPCR pharmacology using GIRK current recordings. Specifically, 
molecular features of ligand binding sites and implications for signaling were explored. 
Details regarding GPCR-ligand interactions will inform future drug development.  
The aims are:  
 To determine if the conserved residue D2.5069 in the M2R constitutes a part of the 
voltage-sensor, mediating voltage-dependent agonist-potency (paper I).  
 
 To determine if the aripiprazole-derived, putatively β-arrestin-selective, D2R ligand 
UNC9994 couples to G protein signaling pathways at D2R and D3R (paper II).  
 
 To explore binding properties and kinetics of aripiprazole radioanalogues of varying 
lipophilicity at the D2R (paper III). 
 
 To experimentally and computationally characterize how a secondary binding pocket 






3.1 MOLECULAR BIOLOGY 
Receptor, accessory protein and ion channel cDNAs were acquired from Genscript 
(Piscataway, NJ). cDNAs encoding the long-isoform human D2R (including WT, V91A, 
L94A and E95A), D3R and β-arrestin-2 were in the pXOOM vector, which includes the 
Xenopus globin gene (118). All mutations were verified by sequencing. cDNAs encoding 
RGS4 (from the Missouri cDNA Resource Center; www.cdna.org), GIRK1 and GIRK4 
(provided by Dr. Terence Hebert, University of Montreal, Canada) were in pCDNA3 
(Invitrogen). cDNAs encoding M2R (from Dr. Hanna Parnas, Hebrew University of 
Jerusalem, Israel) and the catalytic subunit of PTX (PTX-S1) were in pGEM-HE. The D69N 
point mutation was introduced to the WT M2R using the QuickChange (Agilent technologies) 
kit according to the manufacturer's instructions. Plasmids were linearized using restriction 
enzymes (D2R WT, V91A, L94A and E95A, D3R, RGS4; XhoI, GIRK1, GIRK4, M2R WT 
and D69N; NotI, PTX-S1; NheI) and the DNA product was purified using the PureLink™ kit 
(Invitrogen; see Fig. 2A). Linearized DNA was transcribed in vitro using the mMessage 
mMachine™ T7 kit (Ambion, Austin, TX). DNA and RNA products were quantified using 
spectrophotometry (Nanodrop, ThermoFisher). 
3.2 XENOPUS LAEVIS OOCYTES AS EXPRESSION SYSTEM 
Oocytes from the female African clawed toad, Xenopus laevis, were surgically isolated 
according to the procedure described in the ethical permit (N245/15), approved by the 
Swedish National Board for Laboratory Animals and the Stockholm Ethical Committee. 
Briefly, the X. laevis was immersed for 15 min in 5.4 mM tricaine methanesulfonate (MS-
222; Sigma) and 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES; 
Sigma; buffered to pH 7.4 using NaOH). Following verification of anesthesia, a minor 
laparotomy was performed to allow for extraction of ovarian tissue, which was transferred to 
a modified Barth’s solution (MBS; 88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 15 mM 
HEPES, 0.33 mM Ca(NO3)2, 0.41 mM CaCl2 and 0.92 mM MgSO4, 2.5 mM sodium 
pyruvate, 25 U/ml penicillin and 25 µg/ml streptomycin, buffered to pH 7.6 using NaOH). 
The abdominal and skin layers were closed separately using 6-0 silk sutures (Ethicon), 
followed by transfer of the X. laevis to a separate tank for observation during the following 24 
hours.  
Isolated ovarian tissue was treated with 1.5 mg Liberase DH (Roche) for 90 minutes, to 
separate the individual oocytes, which were subsequently manually screened for adequate 
staging (stages V-VI (119)) and quality (see Fig. 2A). Oocytes were incubated for 24 hours at 
12°C, and thereafter injected with 50 nl of aqueous RNA solution using Nanoject II 
(Drummond Scientific). The RNA amounts per oocyte were: M2R (WT), 0.2 ng; M2R 
(D69N), 0.7 ng; D2R (WT, V91A, L94A and E95A), 0.2 ng; D3R, 0.2 ng; β-arrestin-2, 5.6 
ng; PTX-S1, 3 ng; RGS4, 40 ng; GIRK1, GIRK4, 1 ng of each. RGS4 is one of several GAPs 
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expressed in native tissues, which speed up the G protein cycle such that GIRK channel 
activity more closely follows receptor occupancy by agonist (120). 
 
3.3 TWO-ELECTRODE VOLTAGE-CLAMP 
X. laevis oocytes of maturation stages V-VI have a diameter around 1 mm, substantially 
larger as compared to neurons or mammalian cell lines. The two-electrode voltage-clamp 
(TEVC) method allows for precise control of the membrane potential, using separate current-
conducting and voltage-following electrodes (121). Activation of GPCRs evoked GIRK 
currents that were recorded using the TEVC technique (Fig. 2B).  
Electrophysiological recordings were performed at room temperature (22°C), 5 to 7 days 
after RNA injection using the CA-1 amplifier (Dagan, Minneapolis, MN). Data were 
acquired at 134 Hz using pCLAMP 8 (Molecular Devices) software. A high-potassium 
solution (64 mM NaCl, 25 mM KCl, 0.8 mM MgCl2, 0.4 mM CaCl2, 15 mM HEPES and 1 
mM ascorbic acid, adjusted to pH 7.4 with NaOH), giving a K+ reversal potential of about -40 
mV, was used for GIRK current recordings. Ascorbic acid was added to prevent the oxidation 
of dopamine. To increase the GIRK currents, oocytes were clamped at -80 mV during 
registrations. Ligands were added to the 20 μl recording chamber by superfusion at 1.5 
ml/min using a computer-controlled, pressure-driven perfusion system (SmartSquirt, 
AutoMate Scientific, Berkeley, CA).  
 
 
Figure 2. Overview of molecular biology, oocyte preparation, electrophysiology and GIRK recordings. A) 
Converging pipeline of molecular biology and X. laevis oocyte harvesting, followed by RNA-microinjection and 
membrane expression of GPCRs and GIRK channels. See Methods 3.1-3.3 for details. B) General principle of 
two-electrode voltage-clamp of X. laevis oocytes. The voltage-sensing electrode (V) registers the intracellular 
voltage (by comparison with the bath electrode, Ref), which is compared to the clamped voltage (Cmd V), and if 
needed a compensatory current is injected into the oocyte via the current-passing electrode (I). The current is 
registered by an amperometer (A), digitized, and analysed. C) Example of dose-response data, e.g. from oocytes 
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co-expressing D2R and GIRK channels. The oocyte is initially clamped to -40 mV and lowered to -80 mV to 
increase the GIRK currents during the recordings. Increasing agonist concentrations (green-yellow-red-purple) 
evoke increasing GIRK currents, which saturate around the purple concentration. Following halted agonist 
administration, the current returns to baseline. The steady-state currents for each concentration may generate 
dose-response data, here plotted semi-logarithmically. Details are not drawn to scale. 
 
3.4 RECORDING PROTOCOLS 
3.4.1 Agonist dose-response curves 
For evaluation of agonist ligands, 3 to 4 increasing concentrations were applied at 35-, 50- or 
100-second intervals to oocytes expressing the respective receptor (see Fig. 2C). The interval 
was determined to ensure maximal or pseudomaximal agonism (for ligands demonstrating 
slow association rates). The agonist-evoked current response was determined by subtracting 
the basal (agonist-independent) current from the agonist-evoked current. Concentration-
responses were subsequently normalized to the mean responses of maximal agonist-evoked 
responses, either in the same oocytes (expressing D2R or M2R; paper I and III) or in other 
oocytes from the same batch (expressing D2R and D3R, the latter desensitizes after agonist 
application; paper II). For dopamine concentration-response data, 4 to 5 increasing 
concentrations of dopamine were applied at 25-second intervals, ending with a response-
saturating concentration (100 μM) of dopamine. 
3.4.2 Antagonist dose-response curves 
For dopamine receptor antagonists, 100 nM dopamine was first applied to provide a baseline 
response, followed by 3 to 4 applications of increasing concentrations of antagonist at 50-100 
second intervals in the continued presence of 100 nM dopamine (paper II and III). This 
allowed for calculation of inhibition constants (Ki) using the Cheng-Prusoff relationship 
(122). For each oocyte, the current amplitude at the end of each antagonist application 
interval was normalized to the control response to 100 nM dopamine obtained at the start of 
the protocol.  
3.4.3 Evaluation of ligand binding kinetics  
Dissociation rates for acetylcholine (paper I) were determined by fitting a monoexponential 
function to the decay following agonist washout. Observed association rates (kobs) for 
antagonists (paper III) were determined by 40 s applications of 100 nM dopamine, followed 
by varying antagonist concentrations in 100 nM dopamine. A monoexponential function was 
fitted to the antagonist phase, and the inhibition time constant was converted to kobs (see 
Methods 3.5.2).  
Dissociation rates and extents of recovery for ligands that antagonize the receptor-evoked 
GIRK channel current (paper III) were determined by application of 1 µM dopamine, 
followed by ligand in 1 µM DA (antagonizing the response), and subsequent application of 
either 1 or 100 µM dopamine. Surmountability was defined as an increased agonist response 
recovery following application of higher agonist concentrations (e.g. 100 µM dopamine vs. 1 




3.5 DATA ANALYSIS 
3.5.1 Dose-response analysis  
Electrophysiological data were analyzed in Clampfit (Axon™ Instruments). Dose-response 
curves were calculated using the variable-slope sigmoidal functions in GraphPad (Prism 
software). Antagonist data were fitted to the equation:  
𝑌 = 𝑏𝑜𝑡𝑡𝑜𝑚 +
1
1 + 10(𝑋−log10 𝐼𝐶50)𝑛
 
where Y is the response as a fraction of 1, bottom is the maximal response inhibition evoked 
by the antagonist, X is the logarithm of ligand concentration, IC50 is the half maximal inhibitory 
concentration and n is the Hill slope. For agonist data, the equation used was:  
𝑌 =
1
1 + 10−(𝑋−log10 𝐸𝐶50)𝑛
 
where EC50 is the half maximal effective concentration of the agonist.  









according to Cheng-Prusoff (122). Data points were shown as mean ± SEM.  
 
3.5.2 Estimation of rate constants  
GIRK current activation or deactivation kinetics were quantified by fitting a monoexponential 
decay function 
𝑞 =  𝑞0 + 𝐴 × 𝑒
−(𝑡−𝑡0)
𝜏  
to data, to estimate the time constant of response decay upon agonist washout. q0 is the initial 
and q the final current amplitude, t0 is the initial and t is the final time point, A is the current 
amplitude at the start of the fit, and τ is the time constant of current increase or decay. 
The association rate constant kon was previously related to the observed association rates, kobs, 
determined using the GIRK assay (109). Briefly, the calculation is based on a three-state 
model of agonist-bound receptor (RA), unbound receptor (R) and ligand-bound receptor (RL; 
see Methods 3.6.1 below), in which the transition between RA and R (agonist dissociation) is 
assumed to be swift compared to the transition from R to RL (ligand binding). At very high 
ligand concentrations, a kinetic roof of the kobs may be reached (109) .  
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By plotting kobs at varying antagonist concentrations, followed by a linear regression, kon was 





where the antagonist concentration was known and the fraction of unoccupied receptors, R0, 
prior to antagonist application was derived from the dose-response curve of agonist at the 
relevant receptor. koff was estimated separately as  







where ln is the natural logarithm and T1/2 is the time for half-maximal response recovery. 





3.5.3 Curve shift assay 
For curve shift experiments, a maximal response was first evoked by application of 1 µM 
dopamine, which was subsequently washed out, followed by the concomitant application of 
dopamine in the presence (or absence, to generate the control EC50; EC50C) of SV-III-130. The 
current amplitude following 500 s of co-application of dopamine and SV-III-130 was 
normalized to the initial response elicited by 1 µM dopamine. To extract EC50 estimates, 
normalized responses to the various concentrations of dopamine applied in the presence of each 
concentration of SV-III-130, or in its absence, were fit by the equation given above to yield 
EC50Lz or EC50C, respectively, where EC50Lz is the EC50 in the presence of a given 
concentration, z, of antagonizing ligand. A Schild plot was generated by plotting; 
log10(EC50Lz/EC50C - 1) against SV-III-130 concentration, and linear regression was used to 
assess the competitiveness of the agonist and ligand interactions. For competitive ligands, the 
slope is expected to be 1, whereas a ligand with negative allosteric effects typically would 
demonstrate a slope  <1 (123).  
 
3.6 KINETIC BINDING MODELS  
Response recovery following D2R antagonism was simulated based on a three-state model 
and experimental kon and koff values for ligands and dopamine. For antagonists, kon were 
derived from kobs, and koff from response recovery experiments using supramaximal 
dopamine concentrations (100 µM). For dopamine, koff was derived from previous reports 
using the GIRK assay (124), and kon calculated from the EC50 value. kon to irreversibly bound 
states was calculated for the insurmountable ligand SV-III-130, based on the fraction of 
response recovery observed after 125 s, assuming that the insurmountable fraction represents 
the irreversibly bound state.   
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3.6.1 Three-state competitive binding model 
Competitive ligand binding (see e.g. Fig. 1A or C), in the presence of an agonist, was 
simulated using a three-state model. RA represents agonist-bound receptor, mediating GIRK 
activation, in the competitive binding model  
 
where R, RA and RL denote unbound receptor, agonist-bound receptor and (competing) 
ligand-bound receptor, k1, k-1, k3 and k-3, association and dissociation rate constants for 
competing ligand and dopamine respectively, L denoting ligand and A agonist (dopamine).  
3.6.2 Four-state irreversible binding model of induced-fit type  
Irreversible ligand binding was simulated by an induced-fit binding model lacking a 
dissociation from the second binding step (see e.g. Fig. 1E),  
 
where RL2 denoted the irreversibly bound receptor and k2 the association rate to the RL2 
state. For SV-III-130, k2 was set to 0.01 s
-1, based on the observation that approximately 36% 
(=1/e) recovery would be observed after 100 s application of 1 µM SV-III-130 in 1 µM DA.  
Kinetic binding models were evaluated using Matlab 2018a (MathWorks). The RA fraction, 
representing the fraction coupled to GIRK channels, was plotted as a function of time 
(response recovery simulations) or concentration (dose-response simulations).  
 
3.7 MOLECULAR DYNAMICS 
Receptor-ligand complexes were generated based on docking of SV-III-130 to the crystal 
structure of the D2R (PDB code: 6CM4 (7)). The complexes were placed in a lipid bilayer, with 
aqueous solution surrounding the membrane and receptor-ligand complex. Using the 
Accelerating bio-molecular dynamics simulation package (125), the complex was minimized, 
equilibrated and followed by production runs of 3.2 µs, which were used for analysis. Ligand 
receptor contacts were quantified using the get_contacts script (126). The computed ratio 




3.8 STATISTICAL ANALYSIS 
Current amplitudes, extents of recovery and dissociation half-lives were compared using the 
Student’s t-test. Concentration-response curves were compared using analyses of variance (F-
test), to assess differences in pEC50. Observed association rates were plotted against 
antagonist concentrations, and linear regressions were used to determine the slope and kon. 
p<0.05 was considered significant. 
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4 RESULTS AND DISCUSSION 
4.1 PAPER I 
In this study, we investigated the putative voltage-sensing residue in the M2R by expression 
of the uncharged D69N mutant and GIRK channels in oocytes. Expression levels of the M2R 
D69N allowed for functional characterization of agonist-induced currents at -80 mV and 0 
mV using the TEVC technique. The results suggested similar reductions of WT (pEC50 = 
7.82 ± 0.04 at -80 mV and pEC50 = 7.52 ± 0.05 at 0 mV) and D69N receptor potencies 
(pEC50 = 6.80 ± 0.07 at -80 mV and pEC50 = 6.47 ± 0.03 at 0 mV) at depolarized potentials, 
i.e.; a ~2-fold increased EC50 at 0 mV compared to -80 mV.  
For the M2R, two prevailing hypotheses regarding voltage-sensing residues have been 
suggested; either D69 or three tyrosine residues, Y104, Y403 and Y426 (see Introduction, 
1.6). Our results contradict previous experimental and computational studies, which have 
attributed a role to D69 in the voltage-sensing of M2R and other GPCRs (71, 72, 127). 
Instead, our results are in agreement with the hypothesis that Y104, Y403 and Y426 are 
responsible for voltage-dependent agonist potency of the M2R (73). These findings have 
implications for understanding the mechanism underlying the depolarization-induced 
reduction of acetylcholine-evoked GIRK currents in sinoatrial node cardiomyocytes. In the 
central nervous system, e.g. for dopaminergic projections, the role of voltage-dependent 
agonist potency and efficacy in regulating presynaptic transmitter release, as well as 
postsynaptic transmission and neuronal firing patterns, remains largely unexplored. 
Reduced M2R WT and D69N potencies at depolarized potentials were related to increased 
agonist dissociation rates. Due to small GIRK current amplitudes observed at depolarized 
potentials for the M2R D69N, agonist association kinetics were difficult to characterize. The 
small currents may be related to the pronounced constitutive activity of the M2R D69N, 
which reduces the fraction of inactive receptors available to be activated by an agonist. In all, 
the implications of membrane potential on agonist binding kinetics may provide details 
regarding which receptor region that is involved in voltage-sensing and inform future studies 
on voltage-sensing residues in GPCRs.  
 
4.2 PAPER II 
In this study, we investigated a potential G protein-coupling of the proposed fully β-arrestin 
selective D2R ligand, UNC9994 (45, 117). In oocytes expressing D2R and GIRK, potent 
partial agonist efficacy of UNC9994 was observed at D2R-evoked GIRK currents (pEC50 = 
6.73±0.4, Emax = 14.5±2.8%), indicating G protein-coupled signaling. The partial agonist 
efficacy of UNC9994 on GIRK activation was abolished by co-expression of PTX-S1 but 
retained in oocytes co-expressing D2R and β-arrestin-2. These findings contradict previous 
investigations (45, 117), where no G protein agonist or antagonist activity of UNC9994 was 
observed at the D2R.  
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UNC9994 demonstrated higher potency and efficacy at the D3R, eliciting almost full agonism 
(pEC50 = 7.21±0.55, Emax = 89.1±24.3%). Possibly, such D3R interaction may address the 
proposed beneficial antipsychotic effects of UNC9994 in rodents (45, 117). Interestingly, the 
D3R-preferring ligand cariprazine has demonstrated superior efficacy against negative 
symptoms in patients with schizophrenia as compared to the atypical antipsychotic 
risperidone, thereby addressing a previously untargeted symptom domain (128). 
The suggested binding of UNC9994 at the OBP of the D2R suggests an ability to compete 
with dopamine binding (129), and thereby interfering with endogenous activation of G 
protein signaling pathways. Additionally, the UNC9994 binding mode raises questions 
regarding the interactions underlying β-arrestin signaling bias. For lysergic acid diethylamide, 
both the residence time and the β-arrestin signaling efficacy at the 5-HT2AR were reduced 
following a mutation in the second extracellular loop (ECL2); L209A (130). Structure-
functional selectivity-relationship investigations at the D2R suggested ligand interactions with 
the ECL2, specifically with I184, over interactions with serine residues of transmembrane 
helix 5, to bias towards β-arrestin signaling (131). The broader picture of binding kinetics and 
ligand-receptor interactions governing β-arrestin bias is continuing to be revealed.  
 
4.3 PAPER III 
In this study, we investigated a series of aripiprazole (Abilify®) radioanalogues, with varying 
aliphatic linker lengths that connects the primary and secondary pharmacophores, at the D2R. 
SWR-1-8, SV-III-130 and SWR-1-14 have aliphatic linkers of 3, 4 and 5 carbons 
respectively, with increasing lipophilicity (Fig. 3). Interestingly, SV-III-130 demonstrated 
potent interactions (pKi = 8.57±0.05) and an insurmountable binding at the D2R (fraction of 
response recovery following antagonism, agonist concentration: 0.20±0.18, 1 µM DA, and 
0.23±0.03, 100 µM DA), effects not observed for SWR-1-8 (pKi = 8.01±0.18, fraction of 
response recovery following antagonism, agonist concentration: 0.27±0.06, 1 µM DA, and 
0.91±0.09, 100 µM DA) or SWR-1-14 (pKi = 7.70±0.13, fraction of response recovery 
following antagonism, agonist concentration: 0.37±0.04, 1 µM DA, and 0.98±0.12, 100 µM 
DA). Thus, the findings are not in agreement with a strict relationship between lipophilicity 
and insurmountable binding.  
The higher potency of SV-III-130 was mediated by both increased association and decreased 
dissociation rates. Insurmountable binding may be consistent with either a competitive or a 
non-competitive (e.g. allosteric) binding mechanism. Adaptation of the GIRK activation 
assay provided curve-shift data of SV-III-130 at varying agonist concentrations. The resulting 
Schild plot demonstrated a slope close to unity (1.07±0.19, R2 = 0.97), suggesting a 




Figure 3. Structures of aripiprazole, SWR-1-8, SV-III-130s and SWR-1-14. Note the shared aliphatic 4 carbon 
linker in aripiprazole and SV-III-130s. The piperazine moiety constitutes the primary pharmacophore and the 
tetrahydroquinolinone moiety constitutes the secondary pharmacophore.  
The role of the 4 carbon linker was further investigated by alanine mutation of SBP residues 
V91, L94 and E95, presumed to contact the secondary pharmacophore of SV-III-130 (132). 
D2R V91A and E95A reduced the potency (pKi = 7.63±0.16 for V91A and pKi = 7.97±0.13 
for E95A) and abolished the insurmountability of SV-III-130, whereas the D2R L94A 
mutation retained the potency (pKi = 8.95±0.17 for L94A) and abolished the 
insurmountability (fraction of response recovery following antagonism, agonist 
concentration: 0.32±0.05, 1 µM DA, and 0.64±0.11, 100 µM DA). Interestingly, the time to 
half-maximal response recovery of SV-III-130 from D2R L94A (T1/2 = 107.7±11.4 s, 100 µM 
DA) resembled that from D2R WT (T1/2 = 110.7±14.8 s, 100 µM DA), although a pronounced 
surmountability (agonist competition) was observed, suggesting a similar dissociation rate of 
SV-III-130 from the L94A mutant and from (at least a fraction of) WT D2R. These findings 
support a crucial role of V91, L94 and E95 for maintaining the stability of the D2R SBP and 
allowing secondary pharmacophore interactions.  
To further characterize the competitive, but insurmountable, binding mechanism of SV-III-
130 at the D2R, binding models were adapted based on experimental data (see Methods 3.6 
and (9)). A competitive, three-state, ligand-agonist-receptor binding model (109), captured 
the behavior observed in response recovery experiments with SWR-1-8 and SWR-1-14. 
Based on the seemingly irreversible binding of SV-III-130 to a fraction of D2R, as observed 
during our experimental timescale, two ligand binding steps were included in a second 
model: First, a reversible step followed by an irreversible one. This four-state model 
replicated the experimental findings from response recovery experiments with different 
agonist concentrations. To evaluate the induced-fit binding model of SV-III-130 at the D2R, 
an inductive approach was undertaken; prolonged application of SV-III-130 at the D2R would 
be expected to extinguish the response recovery, according to the model. In the corresponding 
experiments, a prolonged (400 s) application of SV-III-130 yielded no response recovery, in 
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agreement with the model. Additionally, the four-state model replicated the experimental 
curve-shift assay for SV-III-130 at D2R WT.  
To further investigate the role of L94 in the SBP interaction with the secondary SV-III-130 
pharmacophore, molecular dynamics simulations were conducted based on the previously 
published crystallographic D2R structure (7). The simulations suggested interactions between 
the secondary pharmacophore of SV-III-130 and W100 (in the ECL1) and I184 (in the ECL2) 
of the WT D2R. Similarly, at the L94A D2R, the secondary pharmacophore interacted with 
W100 and I184, although W100 relocated into the cavity previously formed by L94, thereby 
not sealing the SBP, and possibly increasing the probability of SV-III-130 egress.  
The results suggest an insurmountable binding of SV-III-130 at the WT D2R, which might 
address the slow and limited displacement of [11C]-SV-III-130 following induced endogenous 
dopamine release in non-human primates (133). Similarly, the reduced displacement of other 
D2R ligands in PET studies may potentially be related to an induced-fit binding mechanism 
(9). In general, reduced, and slow, drug dissociation could be beneficial in the design of a 
PET radiotracer or long-acting drug.  
Mechanistically, the proposed binding mechanism implies that the primary pharmacophore of 
SV-III-130 first binds to the OBP and also to the SBP in an open conformation. In the next 
step, the SBP undergoes a conformational change which closes the extracellular loops 1 and 2 
over the ligand through an induced-fit mechanism (9). For ligands with two pharmacophores, 
a heterobivalent binding mode may be possible (8). However, for SV-III-130, the 
experimental data on recovery from D2R antagonism, recorded during a short timeframe (400 
s), was recapitulated by an irreversible binding model of induced-fit type. Response 
recoveries from antagonism by SWR-1-8 and SWR-1-14 were captured by three-state, 
competitive binding models. 
Based on the L94A D2R mutation, which increased the response recovery following SV-III-
130 antagonism, and in vivo observations of limited agonist-mediated displacement of [11C]-
SV-III-130 (133), an induced-fit binding mechanism was proposed and experimentally tested. 
Previous descriptions of non-covalent irreversible GPCR-ligand interactions have been 
described for risperidone at the 5-HT7R (134, 135).  
 
4.4 LIMITATIONS AND ETHICAL CONSIDERATIONS 
Experimentally, papers I-III rely on TEVC investigations of X. laevis oocytes, with several 
shared methodological limitations. Heterologous expression systems demonstrate differences 
compared to in vivo conditions, e.g. in lipid constitution of the cell membrane, co-expression 
of proteins, post-translational modifications and trafficking mechanisms, and should be 
regarded as models. The GIRK assay implies that GPCR activation is transmitted to GIRK 
channels. The coupling efficiency between GPCR and GIRK is increased using a GAP (here 
RGS4), thereby providing binding and kinetic values in agreement with radioligand binding 
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studies (109). Batch-dependent variations in GPCR and GIRK expression were reduced 
whenever possible by normalizing data to the same oocytes, or in some cases (paper II), to 
oocytes from the same batch. The use of simple kinetic models to explain experimental data 
(paper III) might not provide a complete picture of the in vivo pharmacology, but rather a 
theoretical model. The explanatory value of such models should be carefully evaluated; for 
SV-III-130s, we first simulated the expected response recovery following a prolonged SV-III-
130 application to D2R, and thereafter conducted the corresponding experiment.  
The use of X. laevis oocytes for the present two-electrode voltage-clamp require 
consideration of the 3Rs; Replacement, Reduction and Refinement (136). Replacement 
would imply using different biological cells or methods for analysis of receptor-ligand 
interactions, e.g. assays based on mammalian cell lines. RNA injection of oocytes provides a 
precise control of stoichiometry and a ground for reproducibility, as compared to 
corresponding transfections of multiple constructs in mammalian cell lines. Alternative 
methods may be radioligand binding or fluorometric assays, although these have specific 
drawbacks with regard to functional measurements and kinetic investigations.  
Reduction is fundamental in the use of X. laevis oocytes; e.g. by reusing the X. laevis. 
Additionally, multiple experiments should be conducted for each oocyte extraction, to 
optimize the use of the oocytes. Refinement is conducted by using MS-222, a preferred 






In this thesis, GPCR-ligand interactions in the M2R and D2R were explored using 
electrophysiology and computations.  
 
Voltage-sensing properties of the M2R were not mediated by D
2.50 (paper I). Instead, the 
findings may support the hypothesis of three tyrosine residues (Y104, Y403 and Y426) acting 
as voltage sensors in the M2R, as proposed by Barchad-Avitzur et al. (73).  
 
The proposed β-arrestin-selective D2R ligand, UNC9994, activated GIRK channels via D2R 
and D3R, in a G protein-dependent manner, and in the presence of β-arrestin (paper II). 
UNC9994 seemed more potent and efficacious at the D3R, as compared to D2R. In the light 
of other investigations suggesting an inability of ligands to evoke β-arrestin signaling without 
concomitant G protein activation (46), the evidence for completely β-arrestin-selective 
ligands is currently weak.  
 
The bitopic ligand, SV-III-130, displayed an insurmountable binding at the D2R (paper III). 
The two homologues, SWR-1-8 and SWR-1-14 were fully surmountable, which is 
incongruent with a strict relationship between lipophilicity and insurmountable binding. The 
competitive binding observed with SV-III-130 at the D2R was crucially dependent on the 
integrity of the secondary binding pocket. A two-step, irreversible binding model captured 
the experimentally observed binding mechanism of SV-III-130. Additionally, molecular 





6 FUTURE DIRECTIONS 
 
GPCR voltage-sensing mechanisms have mainly been investigated in the M2R. Based on the 
hypothesis that Y104, Y403 and Y426 act as voltage sensors in the M2R, the generalizability 
to other Gαi/o-coupled GPCRs, e.g. the D2R, should be considered. Prospective studies 
investigating inactivating mutations of the corresponding residues in voltage-dependent Gαi/o-
coupled GPCRs, e.g. the D2R or mGlu1R, would address this hypothesis. Additionally, based 
on previous findings of agonist-specific voltage-dependency (probe dependence) (68), 
additional molecular dynamics investigations may provide information regarding the 
structural network involved in GPCR voltage-sensing.  
 
β-arrestin-selective signaling in the absence of G protein activation remains a controversial 
but highly interesting topic; ligands with strong β-arrestin preference would allow for the 
selective study of non-canonical GPCR signaling. Recently, an experimental ligand was 
reported to be a β-arrestin-selective melatonin 1 receptor agonist, but a mixed G protein/β-
arrestin-agonist at the melatonin 2 receptor (136). Further structural-activity relationship 
investigations of the mechanistic underpinnings of G protein/β-arrestin signaling at various 
GPCRs will provide insights for the in silico development of functionally selective ligands. A 
truly β-arrestin-selective D2R ligand would be of substantial value in the research on and 
development of novel therapeutics for psychotic disorders. Based on the physiological 
relevance of β-arrestin-biased ligands at several GPCRs, further investigations of receptor-
ligand interactions conferring signaling bias is of importance.  
 
Demonstration of induced-fit binding of SV-III-130 at the D2R indicates that additional 
ligands could demonstrate similar binding mechanisms. For example, a PET study using the 
radiotracer [18F]-N-methyl-benperidol reported low displaceability from the D2R following 
amphetamine-induced DA competition (138). Based on structural similarities with SV-III-
130, N-methyl-benperidol may bind D2R by an induced-fit binding mechanism. This 
hypothesis could be addressed using the electrophysiology-based GIRK-assay. Further 
investigation of bitopic ligands acting at GPCRs may reveal additional induced-fit binding 
ligands. Also, based on the assumption that the prominent ECL2 of the D2R is a key mediator 
in encapsulating the SBP, it would be valuable to investigate whether an induced-fit binding 
mechanism could be observed at GPCRs with smaller ECL2, e.g. D3R and D4R (7). Finally, 
PET investigations evaluating endogenous dopamine competition with [11C]-SWR-1-8 or 
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